0001209191-23-005234.txt : 20230127 0001209191-23-005234.hdr.sgml : 20230127 20230127161818 ACCESSION NUMBER: 0001209191-23-005234 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230125 FILED AS OF DATE: 20230127 DATE AS OF CHANGE: 20230127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Yuchun CENTRAL INDEX KEY: 0001334365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23563145 MAIL ADDRESS: STREET 1: 170 TRACER LA. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-25 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001334365 Lee Yuchun C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2023-01-25 4 M 0 4000 72.14 A 5875 D Common Stock 2023-01-25 4 S 0 800 312.80 D 5075 D Common Stock 2023-01-25 4 S 0 2621 314.10 D 2454 D Common Stock 2023-01-25 4 S 0 579 314.95 D 1875 D Common Stock 2023-01-26 4 M 0 4000 72.14 A 5875 D Common Stock 2023-01-26 4 S 0 302 315.42 D 5573 D Common Stock 2023-01-26 4 S 0 1140 316.82 D 4433 D Common Stock 2023-01-26 4 S 0 1000 317.95 D 3433 D Common Stock 2023-01-26 4 S 0 478 319.25 D 2955 D Common Stock 2023-01-26 4 S 0 400 320.25 D 2555 D Common Stock 2023-01-26 4 S 0 680 320.94 D 1875 D Stock Option (Right to Buy) 72.14 2023-01-25 4 M 0 4000 0.00 D 2024-05-31 Common Stock 4000 5429 D Stock Option (Right to Buy) 72.14 2023-01-26 4 M 0 4000 0.00 D 2024-05-31 Common Stock 4000 1429 D Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $312.80 (range $312.41 to $313.06). Open market sales reported on this line occurred at a weighted average price of $314.10 (range $313.53 to $314.50). Open market sales reported on this line occurred at a weighted average price of $314.95 (range $314.58 to $315.14). Open market sales reported on this line occurred at a weighted average price of $315.42 (range $315.23 to $315.66). Open market sales reported on this line occurred at a weighted average price of $316.82 (range $316.23 to $317.16). Open market sales reported on this line occurred at a weighted average price of $317.95 (range $317.43 to $318.35). Open market sales reported on this line occurred at a weighted average price of $319.25 (range $318.79 to $319.56). Open market sales reported on this line occurred at a weighted average price of $320.25 (range $319.80 to $320.77). Open market sales reported on this line occurred at a weighted average price of $320.94 (range $320.89 to $320.99). Fully vested. /s/ Christiana Stevenson, Attorney-in-Fact 2023-01-27